Phase I-II trial of methyl-GAG: A Southwest Oncology Group pilot study

W. A. Knight, R. B. Livingston, J. Costanzi, C. Fabian

Research output: Contribution to journalArticle

35 Scopus citations

Abstract

One hundred and nine patients with advanced malignancy, refractory to conventional therapy, were treated with a weekly schedule of methyl-GAG. Ninety-one patients (83%) were less than fully ambulatory. Sixty-five patients were fully evaluable for response. There were two complete and nine partial responses. An additional nine patients had objective tumor regression and were classified as improved. The median duration of response was 5 months. Toxic effects were primarily mucositis (17 patients) and nausea and vomiting (14 patients). Sixty seven patients had no manifestations of drug toxicity. responses observed in a wide variety of solid tumors warrant further clinical trials.

Original languageEnglish (US)
Pages (from-to)1933-1937
Number of pages5
JournalCancer Treatment Reports
Volume63
Issue number11-12
StatePublished - Dec 1 1979

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I-II trial of methyl-GAG: A Southwest Oncology Group pilot study'. Together they form a unique fingerprint.

  • Cite this

    Knight, W. A., Livingston, R. B., Costanzi, J., & Fabian, C. (1979). Phase I-II trial of methyl-GAG: A Southwest Oncology Group pilot study. Cancer Treatment Reports, 63(11-12), 1933-1937.